ArticleClinical, cosmetic and investigational dermatology2026
Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03181893 (A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 2 double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of pf-06823859 in adult subjects with dermatomyositis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Interferon-β (IFNβ) dysregulation contributes to dermatomyositis (DM) pathogenesis. In a previously published phase 2 study, 12-week treatment with dazukibart, an anti-IFNβ monoclonal antibody, reduced disease activity in moderate-to-severe DM. This prespecified secondary analysis evaluated the rapidity of onset of efficacy of dazukibart in DM at time points before Week 12, which may inform treatment decisions. Patients and Methods: This is a secondary analysis of a double-blind, randomized, placebo-controlled phase 2 study (NCT03181893). Adults with skin-predominant (SP) or muscle-predominant (MP) DM received placebo or dazukibart (150 mg/600 mg) at baseline and every 4 weeks. Efficacy outcomes assessed at Weeks 1, 4, and 8 included: SP cohort-change from baseline (CFB) in Cutaneous Dermatomyositis Disease Area and Severity Index activity (CDASI-A), 5D-itch, and Dermatology Quality of Life Index (DLQI) and proportion of patients achieving ≥40% decrease in CDASI-A; MP cohort-Mean Total Improvement Score (TIS), CFB in myositis core set measures, and TIS response. Results: In SP cohort (n=57), statistically significant improvement was observed with dazukibart in mean CFB (placebo-adjusted difference) CDASI-A (Week 4; 150 mg: -10.5 [p=0.0006]; 600 mg: -9.7 [p=0.0004]), 5D-itch (Week 1; 600 mg: -2.0 [p=0.0359]), and DLQI (Week 4; 150 mg: -2.8 [p=0.0249]; 600 mg: -2.7 [p=0.0160]). CDASI-A score decreased by ≥40% in 53.3% (dazukibart 150 mg), 42.9% (dazukibart 600 mg), and 7.7% (placebo) patients at Week 4. In MP cohort (n=18), numerical improvements (sample size not powered to detect statistical significance) with dazukibart 600 mg vs placebo in mean TIS (Week 4) and statistically significant improvements in mean CFB creatine kinase levels (Week 4; p=0.0445) and Patient Global Assessment (Week 8; p=0.0470) were observed. At Week 4, 77.8% and 22.2% (dazukibart 600 mg) vs 66.7% and 0 (placebo) patients achieved minimal and major improvement, respectively. Conclusion: Dazukibart induced rapid improvement in key skin- and muscle-related efficacy outcomes of disease activity in patients with DM. The small sample size of the MP cohort warrants a well-powered Phase 3 study to confirm these Phase 2 proof-of-concept results. Trial Registration: NCT03181893.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.